Patient selection and vitamin E treatment in diabetes mellitus

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 3, 2013, Pages 319-326

  Goldenstein, Hagit ^a   Levy, Nina S ^a   Lipener, Yisrael T ^a   Levy, Andrew P ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

diabetes; glycation; haptoglobin; hemoglobin; oxidative stress

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; ATORVASTATIN; BETA CAROTENE; CALCIUM; CD163 ANTIGEN; HAPTOGLOBIN; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; INSULIN; LOW DENSITY LIPOPROTEIN; POLYUNSATURATED FATTY ACID; PRAVASTATIN; RAMIPRIL;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CALCIUM DEPLETION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DISULFIDE BOND; GENOTYPE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LIPID PEROXIDATION; LIVER FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SELECTION; PRIMARY PREVENTION; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SECONDARY PREVENTION; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; GENOTYPE; HAPTOGLOBINS; HUMANS; INCIDENCE; OXIDATIVE STRESS; PATIENT SELECTION; VITAMIN E;

EID: 84874842760     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.187     Document Type: Review

References (51)

1. Factor SM, Minase T, Sonnenblick EH. Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. Am. Heart J. 99(4), 446-458 (1980).
2. Virtamo J, Rapola JM, Ripatti S et al. Effect of vitamin E and β carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch. Intern. Med. 158(6), 668-675 (1998).
3. de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 357(9250), 89-95 (2001).
4. Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: The St. Francis Heart Study randomized clinical trial. J. Am. Coll. Cardiol. 46(1), 166-172 (2005).
5. Hodis HN, Mack WJ, LaBree L et al.; VEAPS Research Group. α-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: The Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation 106(12), 1453-1459 (2002).
6. Nanayakkara PW, van Guldener C, ter Wee PM et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: Results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch. Intern. Med. 167(12), 1262-1270 (2007).
7. Lee IM, Cook NR, Gaziano JM et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: The Women's Health Study: A randomized controlled trial. JAMA 294(1), 56-65 (2005).
8. Sesso HD, Buring JE, Christen WG et al. Vitamins E and C in the prevention of cardiovascular disease in men: The Physicians' Health Study II randomized controlled trial. JAMA 300(18), 2123-2133 (2008).
9. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSIYPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354(9177), 447-455 (1999).
10. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347(9004), 781-786 (1996).
11. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342(3), 154-160 (2000).
12. Lonn E, Bosch J, Yusuf S et al.; HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA 293(11), 1338-1347 (2005).
13. Waters DD, Alderman EL, Hsia J et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: A randomized controlled trial. JAMA 288(19), 2432-2440 (2002).
14. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebocontrolled trial. Lancet 356(9237), 1213-1218 (2000).
15. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-Analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 142(1), 37-46 (2005).
16. Berry D, Wathen JK, Newell M. Bayesian model averaging in meta-Analysis: Vitamin E supplementation and mortality. Clin. Trials 6(1), 28-41 (2009).
17. Gerss J, Köpcke W. The questionable association of vitamin E supplementation and mortality-inconsistent results of different meta-Analytic approaches. Cell. Mol. Biol. (Noisy-le-Grand) 55(SUPPL.), OL1111-OL1120 (2009).
18. Dotan Y, Pinchuk I, Lichtenberg D, Leshno M. Decision analysis supports the paradigm that indiscriminate supplementation of vitamin E does more harm than good. Arterioscler. Thromb. Vasc. Biol. 29(9), 1304-1309 (2009).
19. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst. Rev. 3, CD007176 (2012).
20. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: Systematic review and meta-Analysis. JAMA 297(8), 842-857 (2007).
21. Yeboah J, McClelland RL, Polonsky TS et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 308(8), 788-795 (2012).
22. Milman U, Blum S, Shapira C et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-Aged individuals with both Type 2 diabetes mellitus and the haptoglobin 2-2 genotype: A prospective double-blinded clinical trial. Arterioscler. Thromb. Vasc. Biol. 28(2), 341-347 (2008).
23. Blum S, Vardi M, Brown JB et al. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics 11(5), 675-684 (2010).
24. Vardi M, Blum S, Levy AP. Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus-natural history of the disease and the effect of vitamin E treatment. Meta-Analysis of the medical literature. Eur. J. Intern. Med. 23(7), 628-632 (2012).
25. Levy AP, Asleh R, Blum S et al. Haptoglobin: Basic and clinical aspects. Antioxid. Redox Signal. 12(2), 293-304 (2010).
26. Asleh R, Marsh S, Shilkrut M et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ. Res. 92(11), 1193-1200 (2003).
27. Goldenstein H, Levy NS, Levy AP. Haptoglobin genotype and its role in determining hemeYiron mediated vascular disease. Pharmacol. Res. 66(1), 1-6 (2012).
28. Langlois MR, Delanghe Jr. Biological and clinical significance of haptoglobin polymorphism in humans. Clin. Chem. 42(10), 1589-1600 (1996).
29. Sadrzadeh SM, Graf E, Panter SS, Hallaway PE, Eaton JW. Hemoglobin. A biologic fenton reagent. J. Biol. Chem. 259(23), 14354-14356 (1984).
30. Rifkind JM, Ramasamy S, Manoharan PT, Nagababu E, Mohanty JG. Redox reactions of hemoglobin. Antioxid. Redox Signal. 6(3), 657-666 (2004).
31. Belcher JD, Beckman JD, Balla G, Balla J, Vercellotti G. Heme degradation and vascular injury. Antioxid. Redox Signal. 12(2), 233-248 (2010).
32. Bamm VV, Tsemakhovich VA, Shaklai M, Shaklai N. Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry 43(13), 3899-3906 (2004).
33. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ. Res. 96(4), 435-441 (2005).
34. Asleh R, Blum S, Kalet-Litman S et al. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 57(10), 2794-2800 (2008).
35. Asleh R, Miller-Lotan R, Aviram M et al. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ. Res. 99(12), 1419-1425 (2006).
36. Conway B, Fried L, Orchard T. Hemoglobin and overt nephropathy complications in Type 1 diabetes. Ann. Epidemiol. 18(2), 147-155 (2008).
37. Asleh R, Levy AP. In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc. Health Risk Manag. 1(1), 19-28 (2005).
38. Levy AP, Hochberg I, Jablonski K et al.; Strong Heart Study. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J. Am. Coll. Cardiol. 40(11), 1984-1990 (2002).
39. Suleiman M, Aronson D, Asleh R et al. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 54(9), 2802-2806 (2005).
40. Roguin A, Koch W, Kastrati A, Aronson D, Schomig A, Levy AP. Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care 26(9), 2628-2631 (2003).
41. Costacou T, Ferrell RE, Orchard TJ. Haptoglobin genotype: A determinant of cardiovascular complication risk in Type 1 diabetes. Diabetes 57(6), 1702-1706 (2008).
42. Simpson M, Snell-Bergeon JK, Kinney GL et al. Haptoglobin genotype predicts development of coronary artery calcification in a prospective cohort of patients with Type 1 diabetes. Cardiovasc. Diabetol. 10, 99 (2011).
43. Melamed-Frank M, Lache O, Enav BI et al. StructureYfunction analysis of the antioxidant properties of haptoglobin. Blood 98(13), 3693-3698 (2001).
44. Costacou T, Evans RW, Orchard TJ. High-density lipoprotein cholesterol in diabetes: Is higher always better? J. Clin. Lipidol. 5(5), 387-394 (2011).
45. Levy AP, Gerstein HC, Miller-Lotan R et al. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 27(11), 2767 (2004).
46. Blum S, Milman U, Shapira C et al. Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-Aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype. Arterioscler. Thromb. Vasc. Biol. 28(3), e18-e20 (2008).
47. Farbstein D, Blum S, Pollak M et al. Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype. Atherosclerosis 219(1), 240-244 (2011).
48. Levy AP, Friedenberg P, Lotan R et al. The effect of vitamin therapy on the progression of coronary artery atherosclerosis varies by haptoglobin type in postmenopausal women. Diabetes Care 27(4), 925-930 (2004).
49. Asleh R, Levy AP. Divergent effects of α-tocopherol and vitamin C on the generation of dysfunctional HDL associated with diabetes and the Hp 2-2 genotype. Antioxid. Redox Signal. 12(2), 209-217 (2010).
50. Lönn ME, Dennis JM, Stocker R. Actions of 'antioxidants' in the protection against atherosclerosis. Free Radic. Biol. Med. 53(4), 863-884 (2012).
51. Fradkin J, Rodgers GP. The economic imperative to conquer diabetes. Diabetes Care 31(3), 624-625 (2008).